Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Chandler Mann

Anesthesiology Kingwood, TX Medical Doctor

NPI 1629069190 CMS profile 119429

24018 Highway 59 N, Kingwood, TX 77339

Open in the dashboard

General payments

$12,189

227 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Chandler Mann of Kingwood, TX is reported in the CMS Open Payments database as having received $12,189 across 227 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $624 32
2024 General $1,743 72
2023 General $4,170 20
2022 General $637 31
2021 General $586 26
2020 General $289 9
2019 General $4,140 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Chandler Mann
  • Anesthesiology median
  • Middle half of Anesthesiology
  • National median

In program year 2025, general payments to Chandler Mann were reported at $624. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.

Show as a table
Year Chandler Mann Anesthesiology median Middle half National median
2019 $4,140 $72 $23–$151 $163
2020 $289 $36 $17–$120 $114
2021 $586 $49 $21–$135 $132
2022 $637 $52 $22–$144 $149
2023 $4,170 $53 $23–$143 $160
2024 $1,743 $55 $25–$150 $164
2025 $624 $58 $26–$153 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $4,664 75 payments
  2. Teva Pharmaceuticals USA, Inc. $3,750 1 payment
  3. Medtronic, Inc. $2,009 91 payments
  4. Abbott Laboratories $884 31 payments
  5. Allergan Inc. $250 2 payments
  6. MML US, Inc. $139 2 payments
  7. Relievant Medsystems, Inc. $80 2 payments
  8. Johnson & Johnson Vision Care, Inc. $70 3 payments
  9. SI-BONE, Inc. $45 2 payments
  10. Nevro Corp. $44 2 payments
  11. Other $252 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $6,950 2 payments
  2. Food and Beverage $4,933 223 payments
  3. Travel and Lodging $306 2 payments
Products named General payments · program years 2019–2025
  1. SPECTRA WAVEWRITER $3,244 4 payments
  2. INTELLIS ADAPTIVESTIM $1,641 80 payments
  3. GENERAL THERAPIES $489 3 payments
  4. PROCLAIM $456 10 payments
  5. GENERAL PAIN MANAGEMENT $391 38 payments
  6. General - Pain Management $198 14 payments
  7. INTELLIS $162 3 payments
  8. ReActiv8 $139 2 payments
  9. RESTASIS $125 1 payment
  10. ETERNA $119 6 payments
  11. Other $1,215 57 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

1,390

Median for Anesthesiology: 322

Drug cost

$31,078

Median for Anesthesiology: $8,738

Branded share of claims

59.1%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 616 $15,579
Fentanyl Generic 44 $4,753
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 155 $4,603
Gabapentin Generic 165 $1,591
Pregabalin Generic 67 $997
Tizanidine Hcl Generic 96 $913
Tramadol Hcl Generic 66 $505
Morphine Sulfate Er Morphine Sulfate Brand 15 $320
Methocarbamol Generic 12 $312
Diclofenac Sodium Generic 24 $309

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 54 billing codes

Paid by Medicare

$208,644

Of which drugs: $53

Medicare patients

415

Average age 74

Services billed

1,913

236 women, 179 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 41%
Diabetes 39%
Depression 29%
Chronic kidney disease 27%
COPD 25%
Osteoporosis 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 16 65 $48

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

227 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Anesthesiology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record